August 23rd 2022
At a median follow-up of 24 months, the best ORR achieved was 77.6% among 58 evaluable patients with large B-cell lymphoma treated with relma-cel.
June 16th 2022
The vice-chair of the Department of Blood and Marrow Transplant and Cellular Immunotherapy at Moffitt Cancer Center discussed more work to be done with CAR T-cell therapies.
June 9th 2022
The vice-chair of the Department of Blood and Marrow Transplant and Cellular Immunotherapy at Moffitt Cancer Center discussed positive data seen with tisa-cel, liso-cel, ide-cel, cilta-cel, and brexu-cel.
June 8th 2022
The chimeric antigen receptor-modified autologous T cells targeting CLDN18.2 had a manageable safety/tolerability profile and promising efficacy.
100% overall response and complete response rates were seen in patients treated with prior CD19 CAR T-cell therapy.
Overall response rate was 41.7% and median progression free survival was 7.2 months.
June 7th 2022
Jason Westin, MD, FACP, leader, DLBCL research team, MD Anderson Cancer Center, discussed results from the ZUMA-7 trial at ASCO 2022.
69% of patients followed up for at least 1 year continue to have an ongoing response.
June 6th 2022
Three of the 9 patients who received the infusion demonstrated best overall response of Stable Disease, and investigators determined dose level 2 to be the biologically effective dose.
Niels van de Donk, MD, PhD, professor, Amsterdam University Medical Centers, discussed positive findings from cohort B of the CARTITUDE-2 study.